Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial
SKIN The Journal of Cutaneous Medicine（2022）
摘要
N/A
更多查看译文
关键词
severe plaque psoriasis,treatment sequence,treatment initiation
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要